

**Amendments to the Claims:**

1. (Currently amended): A chicken astrovirus type 2 (CAstV-2), characterised in that the virus is the CAstV deposited under accession no. I-2932 at the Collection Nationale de Cultures de Microorganisms (CNCM) of the Institute Pasteur, Paris, France or a CAstV-2 that is able to induce antiserum that neutralises the having a neutralizing antibody titre greater than or equal to 128 against the deposited virus as measured in a virus neutralization assay.

Claims 2 – 3 (Canceled)

4. (Previously presented): An immunogenic composition comprising a CAstV-2 according to claim 1, together with a pharmaceutically acceptable carrier or diluent.
5. (Previously presented): The immunogenic composition according to claim 4, characterized in the CAstV-2 is in a live attenuated form.
6. (Previously presented): The immunogenic composition of claim 4, further comprising one or more vaccine components of other pathogens infectious to poultry.
7. (Previously presented): The immunogenic composition according to claim 4, further comprising an adjuvant.

USSN: 10/527,767

Attorney Docket: 2002.016 US

Response to Office Action of December 26, 2007

8. (Previously presented): A method for the preparation of CAstV-2 antigen material, wherein a CAstV-2 according to claim 1 is propagated in a cell culture and subsequently harvested from the cell culture.
  
8. (Previously presented): A method for the preparation of a vaccine according to claim 4, an immunogenic composition, wherein a CAstV-2 according to claim 1 is mixed with a pharmaceutical pharmaceutically acceptable carrier or a diluent.
  
9. (Previously presented): A method for raising an immune response in poultry, against avian astrovirus, comprising administering an immunogenic composition according to claim 4 to poultry.